COVID RESPONSE

Access to this site is authorized and permitted solely for those persons who have agreed to Cypress Consult LLC Terms of Service and who have received a valid User ID and Password. Unauthorized access is a violation of 18 U.S.C. 1030 and may subject you to civil liability and criminal prosecution. 

Client login

   

EMail inquiries

© 2020 Cypress Consult Capital Management, L.P.
One Montague Place 1st Floor East Bay St., P.O. Box N-4906, Nassau, New Providence; 801 Brickell Ave, Miami, FL 33131, USA Cypress Advisers LLC, Corporation Trust Center 1209 Orange St, Wilmington, DE 19804; Rainier Square 1301, Fifth Avenue, Seattle, WA 9810; Woolgate Exchange 25 Basinghall Street London, EC2V 5HA



The Vaccine Trajectory

We are in the process of dedicating substantial financial ressources into US based pharmaceutical companies showing a very promising approach to mission critical COVID-19 rapid testing methodology

The Covid-19 pandemic is the obvious main concern that is on everyone’s mind both on a personal and economic basis.  Everything hinges on the trajectory of potential vaccines and the measures that have to be taken until the vaccine becomes a reality both in development and distribution. 

There now exists a light at the end of the tunnel that did not exist before November 9.  Both Pfizer ($PFE) and Moderna ($MRNA) have announced vaccines with 95% efficacy.  Pfizer expects to produce 50 million doses by the end of 2020 and another 1.3 billion doses in 2021. The Dow Jones, S&P 500 and Nasdaq indexes all closed at record highs on the Pfizer news while the Dow and S&P again hit new highs after Moderna announced its vaccine effectiveness days later.   

The vaccine itself comes with logistical hurdles that make this project much more daunting than just producing a vaccine.  The Pfizer version, for example, must be transported and stored at exceptionally low temperatures.  However, the Moderna vaccine can last for up to six months when stored at standard freezer temperatures. 

Much attention in the market will be given to whether these vaccines stay on their stated schedules, and whether they see any hiccups in distribution.

 We maintain that value inevitably attracts price. We swing big at our best ideas.  Dips and downturns are our double espressos. If it's not ridiculously cheap it's not our cup of tea.  And when the crowd stampedes left, we advance right -- with courage of conviction. 

In short, we Ignore the crowd.